Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2024-08-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
半年报监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board of Harbin Yuheng Pharmaceutical Co., Ltd. It discusses the approval of the 2024 semi-annual report and a proposal regarding the repurchase and cancellation of restricted shares granted to former employees. The document does not contain the actual semi-annual report or detailed financial statements but rather the supervisory board's review and approval of the report and related corporate actions. It also references that the detailed semi-annual report and related announcements are disclosed elsewhere. The document length is short (1326 characters) and serves as an official announcement of meeting resolutions and approvals rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution disclosure, not as the interim report (IR) or other financial report types.
2024-08-23 Chinese
2024年限制性股票激励计划之回购注销部分限制性股票事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's 2024 restricted stock incentive plan, specifically about the repurchase and cancellation of certain restricted stocks. It details the legal review, approvals, authorizations, and compliance with relevant laws and regulations. The document is not a financial report, earnings release, or management discussion but a legal opinion related to a specific corporate action involving stock repurchase and cancellation under a stock incentive plan. This type of document fits best under the category of Regulatory Filings (RNS) as it is a legal opinion and compliance document rather than a financial report or announcement of voting results or capital changes. The document length (5648 characters) and content confirm it is not a brief announcement but a detailed legal opinion letter, which is typical for RNS filings.
2024-08-23 Chinese
关于收到警示函的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the receipt of a warning letter from the China Securities Regulatory Commission Heilongjiang Bureau. It details regulatory actions taken due to discrepancies between the company's 2023 profit forecast and the audited annual report, including references to specific regulatory rules and administrative measures. The document does not contain full financial statements or detailed financial performance data but rather reports on a regulatory warning and related compliance matters. The document length is short (1862 characters) and serves as a regulatory announcement about a compliance issue rather than a full audit or annual report. Therefore, it fits best under Regulatory Filings (RNS).
2024-08-16 Chinese
关于以自有资产抵质押向银团申请流动资金贷款的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the progress of a syndicated loan secured by the company's own assets. It details the approval of the loan, the collateral involved, and the repayment status as of June 13, 2024. The content focuses on financing activities, specifically the use of assets as collateral for a loan and the completion of repayment and release of pledges. There are no financial statements, earnings data, or management discussions present. The document is not a full financial report but an update on capital/financing matters. Therefore, it fits best under the category 'Capital/Financing Update (CAP)'. The document length and content confirm it is not merely an announcement of a report but a substantive update on financing progress.
2024-07-02 Chinese
2024年半年度业绩预告
Regulatory Filings Classification · 95% confidence The document is titled '2024 年半年度业绩预告' which translates to '2024 Half-Year Performance Forecast'. It provides estimated financial results for the period January 1, 2024 to June 30, 2024, including expected net profit and earnings per share. It explicitly states that the forecast has not been audited and that actual financial data will be in the forthcoming half-year report. The document is short (1163 characters) and serves as a performance forecast announcement rather than a full interim report containing actual financial statements or detailed analysis. Therefore, it is not an Interim/Quarterly Report (IR) but rather a regulatory announcement about expected results. Given the nature and length, this fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-07-02 Chinese
第六届监事会第十三次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the resolution of the 13th meeting of the 6th Supervisory Board. It details the election of Ms. Ma Hongzhen as the chairman of the Supervisory Board, including voting results and her biography. The content focuses on board/management changes and does not contain financial data, earnings, or audit information. The document length is short (1001 characters) and is clearly an announcement of a board/management change rather than a full report or financial filing. Therefore, the appropriate classification is Board/Management Information (MANG).
2024-05-17 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.